18/09/2026 US FDA approves Inluriyo + Verzenio for ESR1-Mutated ER+/HER2− Metastatic Breast Cancer Japan Approves Keytruda SC, Expanding Global Commercialization of Alteogen's ALT-B4 Platform Amneal Announces US FDA Approval and Launch of Lanreotide Injection US FDA approves Inluriyo + Verzenio for ESR1-Mutated ER+/HER2− Metastatic Breast Cancer (Ref) Eli Lilly announced that the U.S. FDA has granted full approval to Inluriyo (imlunestrant; estrogen receptor antagonist) + Ver